Skip to main content

Vivo Capital — Portfolio, Page 6

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

165
Companies
$17.2B
Total invested
$136.5M
Avg. check
18
Industries
Biotechnology 21Health Care 15Therapeutics 8Medical 8Pharmaceutical 8Life Science 6+12 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 121144 of 165
Tourmaline Bio
January 2024

Tourmaline Bio is a biotechnology company that develops medicines to treat inflammatory and immune diseases in patients.

Biotechnology · New York$172.5M Post Ipo Equity
Avistone Pharmaceuticals
December 2023

Avistone Pharmaceuticals is a clinical-stage biotechnology company focused on precision oncology therapeutics.

Biotechnology · Beijing$140.7M Series B
EsoBiotec
December 2023

EsoBiotec is a Belgian biotechnology business focused on the discovery of novel cancer therapies.

Biotechnology · Mont-saint-guibert$2.2M Series A
Poseida Therapeutics
August 2023

Poseida Therapeutics is a biopharmaceutical company utilizing gene engineering capabilities to develop targeted therapeutics.

Biopharma · San Diego$50.0M Post Ipo Equity
Gracell Biotechnologies
August 2023

Gracell Biotechnologies is a developer of cancer immune therapy designed to treat cancer.

Biotechnology · Suzhou$100.0M Post Ipo Equity
Ossium Health
July 2023

Ossium Health builds a bone marrow bank to treat blood cancers.

Biotechnology · San Francisco$52.0M Series C
Ocelot Bio
July 2023

Ocelot Bio brings new treatment options to patients with severe liver disease.

Biotechnology · San Diego$3.0M Debt Financing
IGM Biosciences
June 2023

IGM Biosciences is a biotechnology company that develops medicine for people with infectious infections, autoimmune diseases, and cancer.

Biotechnology · Mountain View$107.3M Post Ipo Equity
OneChain Immunotherapeutics
June 2023

OCI develops therapies for leukaemia based on CAR–T.

Biotechnology · Barcelona$7.3M Seed
Elevation Oncology
June 2023

Elevation Oncology is a clinical-stage biopharmaceutical company focused on the development of precision medicines for patients.

Biopharma · New York$50.0M Post Ipo Equity
Icosavax
May 2023

Icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs.

Biotechnology · Seattle$67.8M Post Ipo Equity
Legend Biotech
May 2023

Legend Biotech is a biopharmaceutical company that develops and commercializes novel cell therapies for oncology.

Biotechnology · Piscataway$350.0M Post Ipo Equity
Immune-Onc Therapeutics
January 2023

Immune-Onc Therapeutics is a newly established biopharmaceutical company that develops therapeutic antibodies for cancer treatment.

Biopharma · Palo Alto$25.0M Series B
Pulmobiotics
December 2022

Pulmobiotics is a pre-clinical life sciences company.

Biotechnology · Barcelona$2.0M Grant
Pulmocide
December 2022

Pulmocide is focused on the development of inhaled medicines for the treatment of viral and fungal infections of the respiratory tract.

Biotechnology · London$52.0M Series C
Bonum Therapeutics
November 2022

Bonum Therapeutics creates a technology platform to treat a wide range of diseases.

Biotechnology · Seattle$93.0M Series A
Tricida
October 2022

Tricida operates in the healthcare industry focusing on pharmaceutical business.

Health Care · Menlo Park$125.0M Post Ipo Debt
RayzeBio
September 2022

RayzeBio is a pharmaceuticals company that develops targeted radiopharmaceutical drugs for cancer.

Biotechnology · San Diego$160.0M Series D
Atekka
September 2022

Atekka is a new generation agricultural insurance company.

Agriculture · Paris$4.9M Series Unknown
Inspirna
July 2022

Inspirna is a biotechnology company developing drugs for the treatment of cancer.

Biotechnology · New York$55.1M Series D
Cerebral Therapeutics
June 2022

Cerebral Therapeutics is a clinical-stage pharmaceutical company.

Biotechnology · Aurora$40.0M Series C
Visirna Therapeutics
April 2022

Visirna Therapeutics to develop and commercialize RNAi therapeutics targeting cardiovascular and metabolic diseases.

Biotechnology · Shanghai$60.0M Seed
Aerobiotix
March 2022

Aerobiotix is a privately held company specializing in the development and manufacture of proprietary environmental management devices.

Health Care · Miamisburg$10.0M Debt Financing
Ablaze Pharmaceuticals
November 2021

Ablaze Pharmaceuticals is a clinical-stage pharmaceutical company.

Biotechnology · Jingan$75.0M Series A

Where Vivo Capital invests

Biotechnology21
Health Care15
Therapeutics8
Medical8
Pharmaceutical8
Life Science6

About Vivo Capital's portfolio

How many companies has Vivo Capital invested in?

Vivo Capital has invested in 165 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Vivo Capital invest in?

Vivo Capital's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Pharmaceutical. The firm invests across 18 different industry categories.

What is Vivo Capital's largest investment?

Among tracked funding rounds, Legend Biotech received $350.0M in a Post Ipo Equity round. Vivo Capital's total known invested capital is $17.2B.

What is the average investment size for Vivo Capital?

Vivo Capital's average investment size is $136.5M across its portfolio of 165 companies.

What are Vivo Capital's most recent investments?

Recent Vivo Capital portfolio additions include Tourmaline Bio, Avistone Pharmaceuticals, EsoBiotec, Poseida Therapeutics, Gracell Biotechnologies. These companies were founded in 2020 or later.

Reach the founders behind these 165 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →